Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
biotech
8
×
life sciences
national blog main
new york blog main
8
×
new york top stories
san francisco blog main
san francisco top stories
boston blog main
clinical trials
fda
boston top stories
boulder/denver blog main
boulder/denver top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
deals
glaxosmithkline
investing
pfizer
bristol-myers squibb
eli lilly
europe blog main
europe top stories
immunotherapy
novartis
What
days
8
×
biotech
roundup
bio
ahead
annual
cancer
companies
drug
hasn’t
home
ipo
ipos
slowed
summer
time
abbvie’s
activity
airport
alliance
ambien
american
apocalypse
arrival
asco
attendees
attention
august
babies
beds
biofourmis
birth
born
breastfeed
bristol
bucks
busy
buy
calls
camp’s
Language
unset
Current search:
biotech
×
" new york blog main "
×
photo
×
days
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
5 years ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More